ORKA•benzinga•
Oruka Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial Of ORKA-001, The Company's Novel, Subcutaneously Administered, Half-life Extended Monoclonal Antibody Targeting IL-23p19
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga